IN8bio Presents Data on Gamma-Delta T Cell Therapy for Glioblastoma at ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
IN8bio, Inc. (NASDAQ:INAB) presented promising preliminary clinical data for its gamma-delta T cell therapy, INB-200, at the 2024 ASCO Annual Meeting. The data showed that 92% of patients treated with INB-200 exceeded a median progression-free survival of 7 months, indicating positive treatment effects for glioblastoma.
June 03, 2024 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio presented encouraging preliminary data for its INB-200 therapy at ASCO 2024, showing 92% of patients exceeded a median PFS of 7 months. This highlights the potential of INB-200 as a first-in-class therapy for glioblastoma.
The positive preliminary data presented at a major oncology conference (ASCO) is likely to boost investor confidence in IN8bio's potential, leading to a short-term increase in stock price. The high percentage of patients showing improved progression-free survival is a strong indicator of the therapy's efficacy.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100